BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Creatine kinase brain (CKB); microRNA-483-5p (miR-483-5p); microRNA-551a (miR-551a)

February 19, 2015 8:00 AM UTC

Mouse studies suggest upregulating miR-483-5p and miR-551a or inhibiting CKB could help treat and prevent liver metastasis in colon cancer. In mouse xenograft models of metastatic colon cancer, overexpression of miR-483-5p or miR-551a decreased CKB levels and metastasis to the liver compared with no overexpression. In mouse xenograft models of metastatic colon cancer, the CKB inhibitor cyclocreatine or shRNA knockdown of CKB decreased liver metastasis compared with vehicle or scrambled control shRNA. Ongoing studies include developing small molecules that prevent phosphocreatine uptake by colon cancer cells.

Cyclocreatine is a research agent...